About Enveric Biosciences

We Are a Patient-Centric

Biotechnology Company

We Strive to Extend and Enhance Quality of Life

Development Approach

Enveric Biosciences’ product development approach is focused on best serving the needs of patients, physicians, regulators, and payors in high-value market segments where an evidence-based approach to care is superior.

  • Enveric Biosciences develops and / or identifies undervalued, under-researched, naturally occurring compounds; researches these compounds in partnership with leading clinics; and plans to partner with targeted pharmaceutical and biotech companies that can leverage their commercialization capabilities to maximize the impact these products can have on oncology physicians and patients in need.
  • Enveric Biosciences assets have existing anecdotal data evidence and strong patient / clinician interest to invest in the continued research of rigorous scientific evaluation. The Company is initially targeting unmet medical needs that lack innovative new therapies in the oncology palliative care space.
  • Enveric Biosciences leverages the scientific expertise of its management team, Board of Directors and Scientific Advisory Board; the Company is in the process of strategically developing these compounds with leading medical centers globally.
  • Enveric Biosciences is actively pursuing assets that are complementary to its palliative care focus and / or can be leveraged in combination with its existing pipeline.

Adding Life to One’s Years Not Just Years to One’s Life

Enveric Biosciences is advancing a pipeline of new-generation, naturally occurring and synthetic compounds to provide palliative care for cancer patients suffering from treatment side effects – adding quality of life to people’s years, not just adding years to their lives.

Chemotherapy Often Causes Adverse Side Effects for Cancer Patients

Enveric is developing product candidates that target skin-related ailments common among cancer patients, including radiodermatitis, pruritus, rashes and dry skin, as well as indications such as chemotherapy-induced peripheral neuropathy, with future areas of focus that may include depression, pain and anxiety.

Enveric Biosciences is targeting these unmet medical needs, which lack clinical innovation, with naturally occurring and synthetic compounds in combination with approved treatments, providing both time- and cost-efficiency on the path to commercialization.

Enveric is focused on establishing better outcomes for cancer patients by enabling patients to receive the best possible care without experiencing the debilitating side effects which will significantly improve patient quality of life at the same time.

We Bring Expertise in Cancer, Research, and Drug Development

Enveric Biosciences has assembled a management team, Board of Directors and Scientific Advisory Board of leading oncology experts with expertise in the research and development of naturally occurring compounds such as cannabinoids. The team has extensive experience in new drug development, clinical practice, and clinical research, to rapidly advance a pipeline of novel medicines as an adjunct to standard of care treatments initially focused on support care and combination therapies for cancer.

Management Team

David Johnson

Chairman and Chief Executive Officer

Former CEO of Convatec, oversaw the $4.1B spin out of Convatec from Bristol Myers Squibb; former CEO of Alliqua Biomedical, a developer of wound care technologies.

Carter Ward

Chief Financial Officer

Finance leader with extensive public company leadership experience in life sciences, SEC reporting and capital markets.

Robert G. Wilkins, M.D.

Chief Medical Officer

Former Medical Director at Abbott Laboratories. Business Development / Strategic planning roles with Baxter Healthcare & Battelle. Senior executive and consulting roles with multiple biomedical start-ups.

Avani Kanubaddi

Chief Operating Officer

Former CEO of Welmedix, led brand sale to PE back healthcare company in 2019. Former Director at BMS/ConvaTec and Wyeth/Pfizer in Medical Device, Consumer Health segments.

Board of Directors

David Johnson

Chairman and Chief Executive Officer

George Kegler

Director and Chair of the Audit Committee

Scientific Advisory Board

Vice Chair, Department of Radiation Oncology, Chief, Brachytherapy Service, Memorial Sloan Kettering Cancer Center
Specialization in Clinical Research

Director, Cancer Rehabilitation and Survivorship
Cedars-Sinai Cancer Center

Professor, St. George’s University of London
Specialization in Oncology Research

Neuro-Oncologist, Sunnybrook Research Institute
Professor, University of Toronto
Specialization in Clinical Research

Professor, Neurobiology, Weizmann Institute
Specialization in Oncology Research, Patent Contributor

We Collaborate with Industry Leaders

Enveric Biosciences has developed partnerships with leading global institutions for researching, developing and commercializing its naturally occurring compounds. Together with our partners, we have the potential to accelerate the fast and affordable path to pharmaceutical development efforts, market entry, data collection, and analysis.

Research capabilities
Domain experience in cancer and cannabinoids

Research capabilities
Patient access

Access to proprietary compounds and data
Clinical research experience and resources in Israel

Opportunity to Improve Outcomes in At-Risk Patients

Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects.